Loading the session
Loading the session
Loading instrument
$39.50
−24.79%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:28 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
9.8M shares were sold short at the 15 Oct 2026 settlement, 12.2% of the 80.4M shares outstanding; covering them would take 8.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +17.6% (SPY −1.6%, XLV +13.5%). 3 months: +13.8% (SPY −0.4%, XLV +15.5%). 1 year: +45.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VCYT, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $52.52 was 17.0% above its 50-day average ($44.90) and 22.3% above its 200-day average ($42.96). It has closed above the 200-day for 32 sessions, since 22 Sep 2026. The 50-day average crossed above the 200-day on 5 Jun 2026, 105 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $52.52 on 4 Nov 2026: 13.8% below the 52-week high of $60.91 (30 Jun 2026) and 78.3% above the low of $29.46 (27 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
May 6, 2026
+24.93%November 5, 2025
+27.46%November 3, 2022
+24.26%